Banc of America said a potential catalyst for Trimeris (TRMS)' sales of Fuzeon, an HIV drug, has been delayed by at least one year.
Wednesday, Trimeris and its partner Roche had said they received a request for more information related to the needle-free injection device the Biojector 2000. Analyst Lei Zhong maintains the view that Fuzeon sales have yet to turn the corner and experience meaningful growth. The analyst continues to look for the evidence needed to gain confidence that Fuzeon's growth will accelerate. Zhong maintains a $10 target and reiterates a sell rating.